Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib induction therapy for moderate to severe ulcerative colitis
NL-OMON39874Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Tofacitinib with Placebo (2 arms). Primary endpoint: Remission at Week 8. Started Oct 2014; status: active, not recruiting.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON39874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39874.